Jocelyn Trokenheim

Vice President, Head of Business Development at Exicure Operating Co.

Jocelyn Trokenheim

Jocelyn Trokenheim

Vice President, Head of Business Development at Exicure Operating Co.

Biography

Ms. Trokenheim most recently served as Vice President of Corporate Development at Takeda Pharmaceuticals where she was responsible for global strategic transactions, such as large-scale M&A, divestitures and strategic partnering.

Overview
RelSci Relationships

419

Contact Data
Trying to get in touch with Jocelyn Trokenheim? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
Relationships
RelSci Relationships are individuals Jocelyn Trokenheim likely has professional access to. A relationship does not necessarily indicate a personal connection.

Co-Founder at Exicure Operating Co.

Relationship likelihood: Strong

Co-Founder at Exicure Operating Co.

Relationship likelihood: Strong

Chief Executive Officer at Exicure Operating Co.

Relationship likelihood: Strong

Chief Operating Officer at Exicure Operating Co.

Relationship likelihood: Strong

Chief Scientific Officer at Exicure Operating Co.

Relationship likelihood: Strong

Chief Financial Officer at Exicure Operating Co.

Relationship likelihood: Strong

Co-Founder at Quanterix Corp.

Relationship likelihood: Strong

Senior Vice President, General Manager Specialty Business Unit at DepoMed Inc.

Relationship likelihood: Strong

Partner at The Column Group LLC

Relationship likelihood: Strong

President & Chief Executive Officer at Angion Biomedica Corp.

Relationship likelihood: Strong

Paths to Jocelyn Trokenheim
Potential Connections via
Relationship Science
You
Jocelyn Trokenheim
Vice President, Head of Business Development at Exicure Operating Co.
Career History
Vice President, Head of Business Development
2018 - Current

Exicure, Inc. engages in the provision of clinical stage biotechnology company developing a new class of immunomodulatory and gene silencing drugs against validated targets. Its 3-dimensional, spherical nucleic acid (SNA™) architecture unlocks the potential of nucleic acid therapeutics in multiple organs which address diseases from inflammatory disorders to oncology. The company was founded by Chad Mirkin and Shad Thaxton in 2011 and is headquartered in Skokie, IL.

Vice President, Head of Business Development
Current

Exicure Operating Co. operates as a biopharmaceutical company commercializing spherical nucleic acid constructs as gene regulation and modulation agents for diseases including applications in oncology, dermatology, neurology, and for immune disorders. The SNA constructs allow the use of oligonucleotide-based therapies to treat diseases in a range of tissue types. The company was founded by Chad A. Mirkin and Colby Shad Thaxton in 2011 and is headquartered in Skokie, IL.

Director of Market Research
Prior

Takeda Pharmaceuticals U.S.A., Inc. develops and markets pharmaceutical products. It offers metabolic and cardiovascular, respiratory and immunology, central nervous system, oncology, and general medicine products. The company was founded in 1998 and is headquartered in Deerfield, IL.

Other Affiliations
This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Jocelyn Trokenheim. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Jocelyn Trokenheim's profile does not indicate a business or promotional relationship of any kind between RelSci and Jocelyn Trokenheim.